peptidylprolyl isomerase A pseudogene 80Genealiases: []
Q-omics provides the consensus-scored PPIAP80 profile across patient tissues and cancer cell-line models. PPIAP80 expression is associated with patient survival in 18 of 34 cancer types, with the highest sampling consensus in STAD. Among the 18 cancer types available for tumor–normal comparison, PPIAP80 is differentially expressed in 8, with the highest sampling consensus in LUAD. Additionally, PPIAP80 RNA expression shows 3,738 significant pathway-activity associations, with the highest sampling consensus in STAD. Together, these results highlight STAD, and LUAD as cancer lineages where PPIAP80 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for PPIAP80 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes PPIAP80 survival associations across molecular data types. PPIAP80 RNA expression shows survival associations in the most cancer types (18), followed by mutation status (2). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible PPIAP80 RNA expression–survival associations across cancer types. High PPIAP80 expression shows unfavorable associations in STAD, ACC, MESO, UCEC and BRCA, but favorable associations in SKCM. The STAD Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify STAD as the clearest survival context for PPIAP80 RNA expression.
This table summarizes PPIAP80 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 8. The strongest signals are observed in LUAD for RNA.
This table ranks reproducible tumor–normal expression differences for PPIAP80. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. PPIAP80 shows higher tumor expression in LUAD, STAD, LUSC, HNSC, KIRP and LIHC. The LUAD box plot shows higher PPIAP80 RNA expression in tumor versus normal tissue (log2 FC = +0.206, t-test p < 0.001).
This table shows molecular features associated with PPIAP80 in patient tissues and cancer cell lines. In patient samples, PPIAP80 shows the broadest associations at the RNA and protein expression levels, with STAD recurring as the lineage with the largest associated feature set.
